A Chinese biotechnology company has reported what it describes as cures in five patients with blood diseases using a CRISPR-based gene editing therapy, according to Endpoints News. The results suggest Chinese genetic medicine developers are producing clinical outcomes that could compete with established Western gene editing companies.
The reported outcomes carry implications for the commercial trajectory of Casgevy, the CRISPR therapy jointly developed by Vertex Pharmaceuticals and CRISPR Therapeutics that became the first approved gene editing treatment when it received FDA clearance in December 2023 for sickle cell disease and transfusion-dependent beta-thalassemia. Casgevy carries a list price of $2.2 million per patient in the U.S., and Vertex has acknowledged slower-than-expected uptake.
The Endpoints News report did not specify which company produced the five-patient results, and the underlying clinical data — including follow-up duration, specific endpoints, and whether patients achieved transfusion independence — were not detailed. Five patients constitute a small dataset, and the term "cure" lacks a standardized clinical definition in gene therapy. In Casgevy's pivotal trials, 93.5% of evaluable sickle cell patients achieved freedom from vaso-occlusive crises for at least 12 consecutive months, and 91.4% of beta-thalassemia patients achieved transfusion independence.
China's gene therapy sector has expanded with government support and a regulatory environment that has moved quickly on clinical trial approvals for advanced therapies. If Chinese CRISPR developers pursue regulatory approvals in Southeast Asia, the Middle East, or Latin America, they could capture patient volume in regions where Casgevy's price is prohibitive. This dynamic mirrors CAR-T therapy, where Chinese-manufactured products have undercut Western pricing by 60% to 80% in some markets.